Infusion Partner Expansion Quince has engaged infusion partners to administer its autologous red blood cell encapsulated drug, signaling a need for specialized infusion networks and patient access channels. Target additional specialty infusion providers and hospital systems to scale EryDex administration, expand geographic reach, and secure payer coverage.

Rare Disease Expansion The acquisition of OrphAI Therapeutics to build a rare pulmonary disease pipeline creates cross-selling and collaboration opportunities, enabling leverage of existing relationships, assets, and capabilities to broaden commercial reach and accelerate market entry.

Regulatory Acceleration FDA Fast Track designation and Special Protocol Assessment support an accelerated regulatory path for EryDex, enabling earlier payer engagement and planning for NDA submissions and EU MAA processes.

Clinical Trial Readiness An international NEAT study in a rare pediatric neurodegenerative disease implies the need for expanded investigator networks, site contracting expertise, and supply chain solutions for autologous cell–based therapies, offering services to CROs, sites, and vendors.

Early Access & Reimbursement Position EryDex within early access programs and payer value discussions by emphasizing reduced immunogenicity and longer circulating half-life of autologous RBC vehicles, supported by outcomes data and potential real-world evidence collaborations.